Table 1.
Key parameters of pilot trials combining hematopoietic stem cell transplantation and kidney transplantation for the purpose of mixed chimerism and tolerance.
| Human leukocyte antigen-matching | Boston |
Northwestern |
Stanford |
||||
|---|---|---|---|---|---|---|---|
| Haploidentical | Haploidentical | Mismatched | Matched | Mismatched | Haploidentical | Matched | |
| Number of mismatches | 2–3 | 2–3 | 0–6 | 0 | 3–6 | 1–3 | 0 |
| Patients included | n = 10 | n = 2 | n = 31 | n = 10 | n = 6 | n = 6 | n = 22 |
| Induction of chimerism | 10/10 | 2 | 30/31 | 8/10 | 2/6 | 5/10 | 21/22 |
| Transient mixed chimerism | 10 | Ongoing | 5 | 8/10 | 2 | 3 | 9 |
| Stable mixed chimerism | 0 | Ongoing | 3 | 0 | 0 | 2 | 7 |
| Full donor chimerism | 0 | Ongoing | 16 | 0 | 0 | 0 | 0 |
| Initially off immunosuppression | 8/10 | 1a/2 | 19/31 | 8/10 | 2/6 | 2/6 | 17/22 |
| Rejectionb | 3 | 0 | 0 | 3 | 2 | 0 | 0 |
| Graft Loss | 3 | 0 | 2 | 0 | 0 | 0 | 0 |
| Remaining off IS | 4/10 | 1a/2 | 19/31 | 5/10 | 0 | 0a | 16a/22 |
| Graft-vs.-host disease | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
aOngoing trial.
bOnly patients where IS was withrawn are included.